{"prompt": "['study with patients recommended doses of any additional coagulation factors used, following the', 'guidance below.', 'The use of aPCC for breakthrough bleed treatment for patients on emicizumab should be avoided if', 'possible, and rFVIIa should be the first option used to treat, starting with no more than 90 g/kg as', 'an initial dose. If aPCC needs to be used, no more than 50 IU/kg should be administered as an initial', 'dose and doses of > 100 U/kg/24 hours or more should be avoided, as cases of TMA and thrombotic', 'events were reported when on average a cumulative amount of > 100 U/kg/24 hours aPCC was', 'administered for 24 hours or more. Investigators should provide or remind patients of the exact dose', 'and schedule of bypassing agents or FVIII required to treat any bleed.', 'When a bleed has occurred, patients (or their legally authorized representative) will be', 'required to report bleed information on an ePRO device where possible, including site of bleed,', 'type of bleed, time of each individual bleed (day, start and stop time), and treatment for', 'bleed (e.g., other than emicizumab in case of breakthrough bleeds). The reason for the use', 'of rFVIla will be documented (e.g., bleeding, preventative dose before activity). Thorough', 'documentation of the treatments for bleeds and/or surgeries will be requested, including agent,', 'start time, dose, route of administration, and number of infusions needed to treat the bleed.', 'Local and central laboratory assessments are required to monitor the risk for', 'thromboembolic events or microangiopathic hemolytic anemia or TMA, as per the Schedule of', 'Activities (Appendix 1', 'Schedule of Activities', '), if bypassing agents are used to treat a breakthrough bleed.', 'Investigators will be asked to contact the Medical Monitor in the event of suspected lack or', 'loss of efficacy of emicizumab in order to discuss a potential increase in emicizumab dose to', '3 mg/kg/week and additional laboratory evaluations (e.g., coagulation tests), as well as to re-', \"evaluate the patient's individual benefit-risk for continuing treatment.\", 'An independent Data Monitoring Committee (iDMC) will be responsible for monitoring safety the', 'duration of the study.', '3.2', 'END OF STUDY AND LENGTH OF STUDY', 'The approximate length of the entire study from the first patient enrolled to the last patient,', 'last visit (LPLV; see below) is approximately 3 years. For each individual patient, the study is', 'expected to last approximately 2 years (patients will receive 3 mg/kg/week emicizumab for', 'the first 4 weeks followed by 1.5 mg/kg/week emicizumab for the remainder of the 2-year', 'treatment period). Patients who discontinue emicizumab prior to the completion of the 2-year', \"treatment period will undergo a Safety Follow-up Visit 24 weeks after the patient's last emicizumab\", 'dose or at 2 years after emicizumab treatment start, whichever occurs first.', 'The end of this study is defined as the date when the last remaining patient has completed', 'the last visit (i.e., LPLV). The study will end when all patients have been treated with', 'emicizumab for 2 years, or earlier, if one of the following is documented:', 'Withdrawal of consent', 'OR', 'Emicizumab - F. Hoffmann-La Roche Ltd', '103 / Protocol MO39129, Version 3']['Completed the Safety Follow-up Visit 24 weeks after discontinuing emicizumab', 'OR', 'Lost to follow-up', 'OR', 'Death.', '3.3', 'RATIONALE FOR STUDY DESIGN', 'The primary objective of this study is to evaluate the overall safety and tolerability of', 'prophylactic administration of emicizumab in patients with congenital hemophilia A who have', 'persistent inhibitors against FVIII. This study is being conducted to build on the safety data', 'that have been obtained as part of the clinical program. The results from this study will be', 'used to substantiate the safety database and provide long-term additional data in patients', 'with hemophilia A who have inhibitors against FVIII. The specific focus will be to characterize', 'any thromboembolic events, microangiopathic hemolytic anemia or TMA, systemic', 'hypersensitivity reactions, anaphylaxis and anaphylactoid events that may occur in patients with', 'hemophilia A treated with emicizumab.', 'The study will enroll approximately 200 patients who will receive emicizumab over a 2-year', 'treatment period. This study design has been proposed to permit the long-term evaluation of', 'the safety and tolerability of emicizumab in a large population of patients with hemophilia A.', '3.3.1', 'Rationale for Emicizumab Dose and Schedule', 'In this study, patients will initially receive prophylactic emicizumab at 3 mg/kg/week', 'subcutaneously for 4 weeks, followed by 1.5 mg/kg/week subcutaneously for the remainder', 'of the 2-year treatment period.', 'The safety results from studies ACE001JP/ACE002JP and BH29884 have shown that', 'emicizumab has been well tolerated in patients with hemophilia A. The maximum clinical', 'dose of 3 mg/kg weekly is associated with a 10.3-fold and 11.2-fold safety margin based on', 'Cmax and area under the curve during the dosage interval (AUCT) results, respectively. No', 'clear differences in the plasma concentrations of emicizumab have been observed between', 'adolescent and adult patients.', 'A substantial reduction in bleeding events has been observed following prophylactic', 'emicizumab treatment, especially at doses 1 mg/kg weekly (Table 9). ABR decreased in all', 'patients, regardless of age or the presence of FVIII inhibitors.', 'Table 9', 'Mean Change (%) in Annualized Bleeding Rates in Patients Enrolled in', 'ACE001JP/ACE002JP', 'Emicizumab dose', '0.3 mg/kg weekly', '1 mg/kg weekly', '3 mg/kg weekly', 'ABR reduction', '-74.5', '-86.2', '-96.5', 'ABR=annualized bleeding rate', 'Median ABRs of 1 and 0 were achieved with weekly maintenance doses of 1 and 3 mg/kg', 'emicizumab.', 'Emicizumab - F. Hoffmann-La Roche Ltd', '104 / Protocol MO39129, Version 3']\n\n###\n\n", "completion": "END"}